Pharmaniaga Berhad (KLSE:PHARMA)

Pharmaniaga Berhad Statistics

Total Valuation

KLSE:PHARMA has a market cap or net worth of MYR 1.54 billion. The enterprise value is 2.21 billion.

Market Cap	1.54B
Enterprise Value	2.21B

Important Dates

The next estimated earnings date is Wednesday, November 26, 2025.

Earnings Date	Nov 26, 2025
Ex-Dividend Date	n/a

Share Statistics

KLSE:PHARMA has 6.56 billion shares outstanding. The number of shares has increased by 0.56% in one year.

Current Share Class	6.56B
Shares Outstanding	6.56B
Shares Change (YoY)	+0.56%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	1.11%
Owned by Institutions (%)	10.95%
Float	2.69B

Valuation Ratios

The trailing PE ratio is 12.64 and the forward PE ratio is 27.65.

PE Ratio	12.64
Forward PE	27.65
PS Ratio	0.39
PB Ratio	3.42
P/TBV Ratio	5.55
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.17, with an EV/FCF ratio of -56.31.

EV / Earnings	51.28
EV / Sales	0.57
EV / EBITDA	5.17
EV / EBIT	16.22
EV / FCF	-56.31

Financial Position

The company has a current ratio of 0.92, with a Debt / Equity ratio of 2.21.

Current Ratio	0.92
Quick Ratio	0.57
Debt / Equity	2.21
Debt / EBITDA	2.32
Debt / FCF	-25.25
Interest Coverage	2.03

Financial Efficiency

Return on equity (ROE) is 29.63% and return on invested capital (ROIC) is 6.74%.

Return on Equity (ROE)	29.63%
Return on Assets (ROA)	3.76%
Return on Invested Capital (ROIC)	6.74%
Return on Capital Employed (ROCE)	21.42%
Revenue Per Employee	1.12M
Profits Per Employee	12,325
Employee Count	3,502
Asset Turnover	1.72
Inventory Turnover	5.71

Taxes

In the past 12 months, KLSE:PHARMA has paid 32.21 million in taxes.

Income Tax	32.21M
Effective Tax Rate	42.04%

Stock Price Statistics

The stock price has decreased by -35.62% in the last 52 weeks. The beta is 0.91, so KLSE:PHARMA's price volatility has been similar to the market average.

Beta (5Y)	0.91
52-Week Price Change	-35.62%
50-Day Moving Average	0.26
200-Day Moving Average	0.24
Relative Strength Index (RSI)	40.64
Average Volume (20 Days)	35,758,190

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KLSE:PHARMA had revenue of MYR 3.92 billion and earned 43.16 million in profits. Earnings per share was 0.02.

Revenue	3.92B
Gross Profit	418.31M
Operating Income	136.49M
Pretax Income	76.61M
Net Income	43.16M
EBITDA	417.40M
EBIT	136.49M
Earnings Per Share (EPS)	0.02

Balance Sheet

The company has 344.15 million in cash and 992.55 million in debt, giving a net cash position of -648.41 million or -0.10 per share.

Cash & Cash Equivalents	344.15M
Total Debt	992.55M
Net Cash	-648.41M
Net Cash Per Share	-0.10
Equity (Book Value)	449.93M
Book Value Per Share	0.16
Working Capital	-144.29M

Cash Flow

In the last 12 months, operating cash flow was -9.02 million and capital expenditures -30.28 million, giving a free cash flow of -39.31 million.

Operating Cash Flow	-9.02M
Capital Expenditures	-30.28M
Free Cash Flow	-39.31M
FCF Per Share	-0.01

Margins

Gross margin is 10.68%, with operating and profit margins of 3.49% and 1.10%.

Gross Margin	10.68%
Operating Margin	3.49%
Pretax Margin	1.96%
Profit Margin	1.10%
EBITDA Margin	10.66%
EBIT Margin	3.49%
FCF Margin	n/a

Dividends & Yields

KLSE:PHARMA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.56%
Shareholder Yield	-0.56%
Earnings Yield	2.80%
FCF Yield	-2.55%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on July 5, 2021. It was a forward split with a ratio of 5.

Last Split Date	Jul 5, 2021
Split Type	Forward
Split Ratio	5

Scores

Altman Z-Score	n/a
Piotroski F-Score	6